Company news

Stoke Therapeutics, Inc. news in 2025

Stoke Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

December 4, 2025

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

December 4, 2025

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

November 30, 2025

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

November 16, 2025

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

November 16, 2025

Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

November 4, 2025

Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 3, 2025

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates

October 29, 2025

Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

October 19, 2025

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

October 8, 2025

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

October 8, 2025

Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer

October 5, 2025

MLAB Biosciences Appoints Dr. Edward M. Kaye as Chair of Scientific Advisory Board

September 15, 2025

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

September 1, 2025

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

September 1, 2025

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

August 27, 2025

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

August 24, 2025

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

August 24, 2025

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 11, 2025

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

August 10, 2025

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

August 6, 2025

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

August 5, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 15, 2025

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 9, 2025

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 9, 2025

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2025

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 12, 2025

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 17, 2025

Stoke Therapeutics Announces CEO Transition

March 17, 2025

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

February 25, 2025

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

February 17, 2025

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7, 2025

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

January 6, 2025

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

January 5, 2025

Calls in 2025

Decks in 2025